echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Class 1 new drug SHR7280 is approved for clinical prevention of premature ovulation

    Hengrui Class 1 new drug SHR7280 is approved for clinical prevention of premature ovulation

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Recently, the CDE official website showed that Hengrui's SHR7280 clinical trial application was approved by the China Food and Drug Administration.


    SHR7280 is a new oral small molecule gonadotropin releasing hormone receptor (GnRHR) antagonist, which can block the binding of endogenous GnRH and GnRH receptors, inhibit the synthesis and synthesis of luteinizing hormone and follicle stimulating hormone and other gonadotropins.


    Previously, SHR7280 has been clinically approved by the Food and Drug Administration for two indications, namely endometriosis and prostate cancer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.